跳至內容

MK-7264

維基百科,自由的百科全書
MK-7264
法律規範狀態
法律規範
  • Investigational New Drug
識別資訊
  • 5-(2,4-diaminopyrimidin-5-yl)oxy-2-methoxy-4-propan-2-ylbenzenesulfonamide
CAS號1015787-98-0  checkY
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard英語CompTox Chemicals Dashboard (EPA)
ECHA InfoCard100.258.106 編輯維基數據鏈接
化學資訊
化學式C14H19N5O4S
摩爾質量353.4
3D模型(JSmol英語JSmol
  • CC(C)C1=CC(=C(C=C1OC2=CN=C(N=C2N)N)S(=O)(=O)N)OC
  • InChI=1S/C14H19N5O4S/c1-7(2)8-4-10(22-3)12(24(17,20)21)5-9(8)23-11-6-18-14(16)19-13(11)15/h4-7H,1-3H3,(H2,17,20,21)(H4,15,16,18,19)
  • Key:HLWURFKMDLAKOD-UHFFFAOYSA-N

MK-7264(英語:Gefapixant)是一種磺胺類藥物,作為嘌呤P2X受體P2RX3英語P2RX3拮抗劑,可用於治療慢性咳嗽英語chronic cough[1][2][3]

參考文獻

[編輯]
  1. ^ Muccino D, Green S. Update on the clinical development of gefapixant, a P2X3 receptor antagonist for the treatment of refractory chronic cough. Pulmonary Pharmacology & Therapeutics. June 2019, 56 ( ): 75–78. PMID 30880151. doi:10.1016/j.pupt.2019.03.006. 
  2. ^ Richards D, Gever JR, Ford AP, Fountain SJ. Action of MK-7264 (gefapixant) at human P2X3 and P2X2/3 receptors and in vivo efficacy in models of sensitisation. British Journal of Pharmacology. July 2019, 176 (13): 2279–2291. PMC 6555852可免費查閱. PMID 30927255. doi:10.1111/bph.14677. 
  3. ^ Marucci G, Dal Ben D, Buccioni M, Martí Navia A, Spinaci A, Volpini R, Lambertucci C. Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications. Expert Opinion on Therapeutic Patents. December 2019, 29 (12): 943–963. PMID 31726893. doi:10.1080/13543776.2019.1693542.